UNSPSC 51373458: Codeine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373458 Codeine/pseudoephedrine is a Commodity code that encompasses pharmaceutical products state and local governments procure for correctional health, public health, and emergency response programs. Recent solicitations show state and local buyers acquiring parenteral pharmaceutical products including intravenous solutions and controlled substances for incarcerated populations, as well as naloxone and drug deactivation systems for community health initiatives. The Washington State Department of Corrections is the primary issuing body in the current pipeline, soliciting parenteral products including controlled substances across eight correctional facilities through a competitive RFQ process. Correctional systems and county health departments represent the core buying base under this code.

Activity is geographically dispersed across Washington and Florida, with the Washington State Department of Corrections' RFQ RFQQK13020 due October 7, 2026 representing the most substantial recent opportunity—the agency anticipates selecting multiple contractors with up to three bidders per region across West, Central, and East zones, and the contract term runs through June 30, 2030 with pricing fixed for the initial two-year period. Seminole County, Florida's IFB 60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; that bid closed July 26, 2023. Set-asides and preferences vary by issuing body—Washington DOC applies a 5% small and diverse business aspirational goal with documented subcontractor inclusion requirements for minority-owned, women-owned, and disadvantaged businesses, while Seminole County's procurement carried no explicit set-aside designations but included E-Verify and drug-free workplace certification requirements.